Drug
Cemiplimab
Cemiplimab: highest development phase Phase 2, developed by Exelixis, Regeneron, United Therapeutics. 6 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Exelixis, Regeneron, United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Cemiplimab NCT07234058 | Phase 2 | Pleural Mesotheliomas |
| Cemiplimab NCT07058012 | Phase 2 | Colo-rectal Cancer |
| Cemiplimab NCT06465329 | Phase 2 | Non-Small Cell Lung Cancer |
| Cemiplimab NCT04046107 | Phase 1/2 | Hepatitis B Virus |
| Cemiplimab NCT06902376 | Phase 1 | Anaplastic Thyroid Cancer |
| Cemiplimab NCT03233139 | Phase 1 | Advanced Malignancies |
Latest
No recent events.
Follow Cemiplimab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.